|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.63 USD | +3.23% |
|
+5.66% | -25.95% |
| 05-07 | Needham Cuts Price Target on Azenta to $33 From $44, Keeps Buy Rating | MT |
| 05-06 | Azenta, Inc., Q2 2026 Earnings Call, May 06, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.1B | - | - | - | ||
| 45.45B | |||||
| 36.09B | - | - | - | - | - |
| 30.98B | |||||
| 30.81B | |||||
| 24.62B |
- Stock Market
- Stocks
- AZTA Stock
- Charts Azenta, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
